TrialBritish journal of cancer2018

Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).

Nuria Romero-Laorden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.